What intravenous antibiotics are recommended for an adult with abdominal wall cellulitis and a possible abscess?

Recommended IV Antibiotics for Abdominal Wall Cellulitis with Possible Abscess

For abdominal wall cellulitis with possible abscess requiring hospitalization, initiate IV vancomycin (15-20 mg/kg every 8-12 hours) plus either piperacillin-tazobactam (3.375 g every 6 hours) or a carbapenem (meropenem 1 g every 8 hours), with urgent surgical consultation for abscess drainage if present. 1

Clinical Decision Framework

Step 1: Determine Infection Severity and Source Control Needs

The abdominal wall location with possible abscess classifies this as a complicated skin and soft tissue infection (cSSTI) requiring hospitalization. The IDSA guidelines specifically define cSSTI as deeper soft-tissue infections and major abscesses requiring IV therapy 1.

Critical action: If imaging or clinical examination confirms an abscess, incision and drainage is the primary treatment and must be performed urgently 1, 2. Antibiotics alone are insufficient for abscess management.

Step 2: Empiric IV Antibiotic Selection

For hospitalized patients with cSSTI, empiric coverage must address:

• MRSA (methicillin-resistant Staphylococcus aureus)
• β-hemolytic streptococci
• Gram-negative organisms (particularly if abdominal wall breach or intra-abdominal source suspected)
• Anaerobes (if concern for intra-abdominal extension)

Primary regimen options 1:

1. Vancomycin 15-20 mg/kg IV every 8-12 hours (A-I evidence)

   • Covers MRSA and streptococci
   • Requires serum drug monitoring
   • Add gram-negative/anaerobic coverage if abdominal source suspected

2. Linezolid 600 mg IV every 12 hours (A-I evidence)

   • Alternative MRSA coverage
   • No monitoring required
   • More expensive

3. Daptomycin 4 mg/kg IV once daily (A-I evidence)

   • MRSA coverage only
   • Cannot be used if pulmonary involvement

Step 3: Add Broad-Spectrum Coverage for Abdominal Wall Location

Because this is abdominal wall cellulitis with possible abscess, you must consider intra-abdominal pathology extension (e.g., perforated appendicitis, diverticulitis, or post-surgical infection). Add one of the following to vancomycin 3:

• Piperacillin-tazobactam 3.375 g IV every 6 hours (increase to 4.5 g every 6 hours if Pseudomonas suspected)
• Meropenem 1 g IV every 8 hours
• Imipenem-cilastatin 500 mg IV every 6 hours

This dual coverage approach is specifically recommended for severe infections requiring broad empiric therapy 4.

Common Pitfalls to Avoid

1. Do not use vancomycin monotherapy for abdominal wall infections—gram-negative and anaerobic coverage is essential if any concern for intra-abdominal source 3

2. Do not delay drainage if abscess is present—antibiotics without source control lead to treatment failure 1, 2

3. Do not use clindamycin empirically unless local MRSA resistance rates are <10% and patient is stable 1

4. Avoid ampicillin-sulbactam—high resistance rates among E. coli make it inappropriate 3

5. Do not use cefazolin alone for purulent cellulitis—it lacks MRSA coverage 1

Duration and De-escalation

• Initial duration: 7-14 days based on clinical response 1
• Obtain cultures from any drained abscess or blood if systemically ill 1, 2
• Narrow antibiotics once culture results available—discontinue unnecessary broad-spectrum agents 3
• Transition to oral therapy when clinically improving, afebrile for 24-48 hours, and able to tolerate oral intake

Special Considerations

If patient has healthcare-associated risk factors (recent hospitalization, nursing home resident, prior antibiotics, indwelling devices), consider adding coverage for resistant gram-negatives and potentially increasing vancomycin to target MRSA with reduced susceptibility 3.

For patients with severe β-lactam allergy, substitute aztreonam 1-2 g IV every 6-8 hours for gram-negative coverage, maintaining vancomycin for gram-positive organisms 3.